Josep Sabaté, M.D.
@josepsabate.bsky.social
🌟 Josep Sabaté | Medical Oncologist.
🎗 Focused on breast cancer care and research.
🏥 Currently at the International Breast Cancer Center (IBCC), Pangaea Oncology Group.
👨👧👦 Proud father of two amazing kids who inspire me everyday.
🎗 Focused on breast cancer care and research.
🏥 Currently at the International Breast Cancer Center (IBCC), Pangaea Oncology Group.
👨👧👦 Proud father of two amazing kids who inspire me everyday.
Reposted by Josep Sabaté, M.D.
Post-hoc TAILORx analysis: In HR+/HER2-, LN- breast cancer w/ RS ≥31, anthracycline (T-AC) improved 5-year DRFI (96% vs 91%, aHR 0.32, p=0.009) and DRFS vs TC. Benefit strongest in tumors >2cm, increasing with RS
Results are alligned w/ other MammaPrint High 2 results
@oncoalert.bsky.social
Results are alligned w/ other MammaPrint High 2 results
@oncoalert.bsky.social
December 13, 2024 at 3:57 PM
Post-hoc TAILORx analysis: In HR+/HER2-, LN- breast cancer w/ RS ≥31, anthracycline (T-AC) improved 5-year DRFI (96% vs 91%, aHR 0.32, p=0.009) and DRFS vs TC. Benefit strongest in tumors >2cm, increasing with RS
Results are alligned w/ other MammaPrint High 2 results
@oncoalert.bsky.social
Results are alligned w/ other MammaPrint High 2 results
@oncoalert.bsky.social
IBCC - International Breast Cancer Center on LinkedIn: #navidad #saludosnavideños #feliz2025
Todas las personas que formamos parte del IBCC os deseamos una Feliz Navidad y un Feliz Año Nuevo, en el que os seguiremos acompañando para afrontarlo, juntos,…
www.linkedin.com
December 25, 2024 at 11:18 AM
Reposted by Josep Sabaté, M.D.
Anthracyclines still have a role in the treatment of those patients with early breast cancer at very high risk of disease recurrence!
December 13, 2024 at 3:42 PM
Anthracyclines still have a role in the treatment of those patients with early breast cancer at very high risk of disease recurrence!
Reposted by Josep Sabaté, M.D.
#SABCS24 #bcsm #OncSky
🧵 COMET study randomized 957 F age 40+ w/ low risk ER+ #DCIS to guideline-concordant care (GCC, immed surgery etc) or active monitoring (AM, serial imaging-> bx/surg etc). At 2y, AM non-inferior to GCC for invasive #breastcancer, BUT important details…
@oncoalert.bsky.social
🧵 COMET study randomized 957 F age 40+ w/ low risk ER+ #DCIS to guideline-concordant care (GCC, immed surgery etc) or active monitoring (AM, serial imaging-> bx/surg etc). At 2y, AM non-inferior to GCC for invasive #breastcancer, BUT important details…
@oncoalert.bsky.social
December 12, 2024 at 11:44 PM
#SABCS24 #bcsm #OncSky
🧵 COMET study randomized 957 F age 40+ w/ low risk ER+ #DCIS to guideline-concordant care (GCC, immed surgery etc) or active monitoring (AM, serial imaging-> bx/surg etc). At 2y, AM non-inferior to GCC for invasive #breastcancer, BUT important details…
@oncoalert.bsky.social
🧵 COMET study randomized 957 F age 40+ w/ low risk ER+ #DCIS to guideline-concordant care (GCC, immed surgery etc) or active monitoring (AM, serial imaging-> bx/surg etc). At 2y, AM non-inferior to GCC for invasive #breastcancer, BUT important details…
@oncoalert.bsky.social
Reposted by Josep Sabaté, M.D.
CDK4/6 inhibitors: mechanisms of resistance and where to find them.
An outside of the box review
Main takeaways:
🛑RB1 loss in #ctDNA predicts poorer PFS
⚠️CCNE1 gain impacts PALOMA-3 outcomes
🧩Role of ESR1 still unclear
Read more👇
www.sciencedirect.com/science/arti...
#bcsm #BreastCancer
An outside of the box review
Main takeaways:
🛑RB1 loss in #ctDNA predicts poorer PFS
⚠️CCNE1 gain impacts PALOMA-3 outcomes
🧩Role of ESR1 still unclear
Read more👇
www.sciencedirect.com/science/arti...
#bcsm #BreastCancer
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): mechanisms of resistance and where to find them
CDK4/6 inhibitors (CDK4/6i) have significantly impacted on the treatment of HR+ HER2 negative (HER2-) metastatic breast cancer (BC) when combined with…
www.sciencedirect.com
December 20, 2024 at 7:50 AM
CDK4/6 inhibitors: mechanisms of resistance and where to find them.
An outside of the box review
Main takeaways:
🛑RB1 loss in #ctDNA predicts poorer PFS
⚠️CCNE1 gain impacts PALOMA-3 outcomes
🧩Role of ESR1 still unclear
Read more👇
www.sciencedirect.com/science/arti...
#bcsm #BreastCancer
An outside of the box review
Main takeaways:
🛑RB1 loss in #ctDNA predicts poorer PFS
⚠️CCNE1 gain impacts PALOMA-3 outcomes
🧩Role of ESR1 still unclear
Read more👇
www.sciencedirect.com/science/arti...
#bcsm #BreastCancer
Reposted by Josep Sabaté, M.D.
Dr. Bianchini describes the 🐘 in the room at #SABCS24.
❓Are PD-L1 and PD1 not created equal in breast?
🔑It is clear, neoadjuvant compared to adj immunotherapy should be given
⚠️ highlights ER low should be included in ICI trials
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
❓Are PD-L1 and PD1 not created equal in breast?
🔑It is clear, neoadjuvant compared to adj immunotherapy should be given
⚠️ highlights ER low should be included in ICI trials
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
December 13, 2024 at 4:51 PM
Dr. Bianchini describes the 🐘 in the room at #SABCS24.
❓Are PD-L1 and PD1 not created equal in breast?
🔑It is clear, neoadjuvant compared to adj immunotherapy should be given
⚠️ highlights ER low should be included in ICI trials
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
❓Are PD-L1 and PD1 not created equal in breast?
🔑It is clear, neoadjuvant compared to adj immunotherapy should be given
⚠️ highlights ER low should be included in ICI trials
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
Reposted by Josep Sabaté, M.D.
No standing ovations at #SABCS24, but maybe there should have been! 🎤 (Granted, I didn’t catch everything in the room.)
For MBC, the #PATINA and #EMBER data bring meaningful progress for patients with ER+ & triple-positive breast cancer. Exciting strides being made.
For MBC, the #PATINA and #EMBER data bring meaningful progress for patients with ER+ & triple-positive breast cancer. Exciting strides being made.
Wrapping up another fantastic #SABCS!
Amazing, practice-changing data were presented.
I’ve updated the algorithms and added key studies from the meeting— I finally ran out of space in HR+ disease!
#SABCS24 @oncoalert.bsky.social
Amazing, practice-changing data were presented.
I’ve updated the algorithms and added key studies from the meeting— I finally ran out of space in HR+ disease!
#SABCS24 @oncoalert.bsky.social
December 13, 2024 at 9:36 PM
Reposted by Josep Sabaté, M.D.
Check out this new systematic review and meta-analysis discussing #AntibodyDrugConjugates in patients with advanced/metastatic HER2-low-expressing #BreastCancer.
🔓https://pubmed.ncbi.nlm.nih.gov/39574495/
@ptarantinomd.bsky.social
🔓https://pubmed.ncbi.nlm.nih.gov/39574495/
@ptarantinomd.bsky.social
December 17, 2024 at 2:30 PM
Check out this new systematic review and meta-analysis discussing #AntibodyDrugConjugates in patients with advanced/metastatic HER2-low-expressing #BreastCancer.
🔓https://pubmed.ncbi.nlm.nih.gov/39574495/
@ptarantinomd.bsky.social
🔓https://pubmed.ncbi.nlm.nih.gov/39574495/
@ptarantinomd.bsky.social
Reposted by Josep Sabaté, M.D.
RLY2608 is a mutant specific PIK3CA inhibitor sparing Wildtype Receptor.
2nd line PFS >11 months with fulvestrant.
Improved safety profile with low grade hyperglycemia, no rash, diarrhea, or oral sores.
Hoping this one moves forward!
#SABCS24 @oncoalert.bsky.social @oncbrothers.bsky.social
2nd line PFS >11 months with fulvestrant.
Improved safety profile with low grade hyperglycemia, no rash, diarrhea, or oral sores.
Hoping this one moves forward!
#SABCS24 @oncoalert.bsky.social @oncbrothers.bsky.social
December 11, 2024 at 9:42 PM
RLY2608 is a mutant specific PIK3CA inhibitor sparing Wildtype Receptor.
2nd line PFS >11 months with fulvestrant.
Improved safety profile with low grade hyperglycemia, no rash, diarrhea, or oral sores.
Hoping this one moves forward!
#SABCS24 @oncoalert.bsky.social @oncbrothers.bsky.social
2nd line PFS >11 months with fulvestrant.
Improved safety profile with low grade hyperglycemia, no rash, diarrhea, or oral sores.
Hoping this one moves forward!
#SABCS24 @oncoalert.bsky.social @oncbrothers.bsky.social
Reposted by Josep Sabaté, M.D.
Updated treatment algorithms for breast cancer now include adjuvant ribociclib and inavolisib, along with key trial names. Thrilled to see we're truly running out of space in HR+ disease—progress is here, with much more to come for all breast cancer subtypes!
November 17, 2024 at 11:04 PM
Updated treatment algorithms for breast cancer now include adjuvant ribociclib and inavolisib, along with key trial names. Thrilled to see we're truly running out of space in HR+ disease—progress is here, with much more to come for all breast cancer subtypes!